Creative Commons source reading · Parkinson’s disease and related disorders
Current and projected future economic burden of Parkinson's disease in the U.S.
Wenya Yang; Jamie L Hamilton; Catherine Kopil; James C Beck; Caroline M Tanner; Roger L Albin; E Ray Dorsey; Nabila Dahodwala; Inna Cintina; Paul Hogan; Ted Thompson
Originally published in NPJ Parkinson's disease · 2020-07-09
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Parkinson's disease (PD) is one of the world's fastest growing neurological disorders. Much is unknown about PD-associated economic burdens in the United States (U.S.) and other high-income nations. This study provides a comprehensive analysis of the economic burdens of PD in the U.S. (2017) and projections for the next two decades. Multiple data sources were used to estimate the costs of PD, including public and private administrative claims data, Medicare Current Beneficiary Survey, Medical Expenditure Panel Survey, and a primary survey ( n = 4,548) designed for this study. We estimated a U.S. prevalence of approximately one million individuals with diagnosed Parkinson's disease in 2017 and a total economic burden of $51.9 billion. The total burden of PD includes direct medical costs of $25.4 billion and $26.5 billion in indirect and non-medical costs, including an indirect cost of $14.2 billion (PWP and caregiver burden combined), non-medical costs of $7.5 billion, and $4.8 billion due to disability income received by PWPs. The Medicare program bears the largest share of excess medical costs, as most PD patients are over age 65.
Results
We estimated that 1.04 million individuals in the U.S. have been diagnosed with PD in 2017, with about 919,000 (89%) eligible for Medicare (91% age ≥65; 9% <65). PD was more prevalent in the ≥65 population (16.9 cases vs. 0.7 per 1,000 population), and more prevalent in men (595,000 males vs. 443,000 females). See Supplementary Table 1 for details.
Discussion
This study provides a comprehensive assessment of the economic burdens of PD in the U.S. We updated cost components included in previous studies, and captured cost components omitted from previous research.
Methods
We used a prevalence-based approach in estimating the economic burdens of PD in 2017. The estimated number of PWPs in 2017 was combined with per-capita cost to derive national economic burden by population characteristics. Figure 4 shows the cost calculation steps and data source for each cost component.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
